These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 18785547)

  • 61. Ciprofloxacin and levofloxacin resistance among methicillin-sensitive Staphylococcus aureus isolates from keratitis and conjunctivitis.
    Marangon FB; Miller D; Muallem MS; Romano AC; Alfonso EC
    Am J Ophthalmol; 2004 Mar; 137(3):453-8. PubMed ID: 15013867
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Comparative antimicrobial activity of levofloxacin and ciprofloxacin against Streptococcus pneumoniae.
    Garrison MW
    J Antimicrob Chemother; 2003 Sep; 52(3):503-6. PubMed ID: 12917240
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Fluoroquinolone resistance of Pseudomonas aeruginosa isolates causing nosocomial infection is correlated with levofloxacin but not ciprofloxacin use.
    Lee YJ; Liu HY; Lin YC; Sun KL; Chun CL; Hsueh PR
    Int J Antimicrob Agents; 2010 Mar; 35(3):261-4. PubMed ID: 20045290
    [TBL] [Abstract][Full Text] [Related]  

  • 64. In vitro antibiotic susceptibilities of ocular isolates in North and South America. In Vitro Antibiotic Testing Group.
    Jensen HG; Felix C
    Cornea; 1998 Jan; 17(1):79-87. PubMed ID: 9436885
    [TBL] [Abstract][Full Text] [Related]  

  • 65. In vitro activity of levofloxacin against gram-positive bacteria.
    Montanari MP; Mingoia M; Marchetti F; Varaldo PE
    Chemotherapy; 1999; 45(6):411-7. PubMed ID: 10567771
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Susceptibility comparisons of normal preoperative conjunctival bacteria to fluoroquinolones.
    Hori Y; Nakazawa T; Maeda N; Sakamoto M; Yokokura S; Kubota A; Inoue T; Nishida K; Tano Y
    J Cataract Refract Surg; 2009 Mar; 35(3):475-9. PubMed ID: 19251140
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Antimicrobial susceptibility testing of newer quinolones against gram positive and gram negative clinical isolates.
    Iffat W; Shoaib MH; Muhammad IN; Rehana ; Tasleem S; Gauhar S
    Pak J Pharm Sci; 2010 Jul; 23(3):245-9. PubMed ID: 20566434
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Antipneumococcal activity of ulifloxacin compared to levofloxacin and ciprofloxacin.
    Pallecchi L; Riccobono E; Montagnani F; Di Maggio T; Mantengoli E; Pollini S; Rossolini GM
    J Chemother; 2011 Oct; 23(5):308-9. PubMed ID: 22005066
    [No Abstract]   [Full Text] [Related]  

  • 69. Urinary bactericidal activity, urinary excretion and plasma concentrations of gatifloxacin (400 mg) versus ciprofloxacin (500 mg) in healthy volunteers after a single oral dose.
    Boy D; Well M; Kinzig-Schippers M; Sörgel F; Ankel-Fuchs D; Naber KG
    Int J Antimicrob Agents; 2004 Mar; 23 Suppl 1():S6-16. PubMed ID: 15037323
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Topical fluoroquinolone use as a risk factor for in vitro fluoroquinolone resistance in ocular cultures.
    Fintelmann RE; Hoskins EN; Lietman TM; Keenan JD; Gaynor BD; Cevallos V; Acharya NR
    Arch Ophthalmol; 2011 Apr; 129(4):399-402. PubMed ID: 21482865
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Identification and pretherapy susceptibility of pathogens in patients with complicated urinary tract infection or acute pyelonephritis enrolled in a clinical study in the United States from November 2004 through April 2006.
    Peterson J; Kaul S; Khashab M; Fisher A; Kahn JB
    Clin Ther; 2007 Oct; 29(10):2215-21. PubMed ID: 18042477
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Comparative in vitro activities of three new quinolones and azithromycin against aerobic pathogens causing respiratory tract and abdominal wound infections.
    Wenzler S; Schmidt-Eisenlohr E; Daschner F
    Chemotherapy; 2004 Apr; 50(1):40-2. PubMed ID: 15084805
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Comparative
    Afriyie DK; Adu LB; Dzradosi M; Amponsah SK; Ohene-Manu P; Manu-Ofei F
    Pan Afr Med J; 2018; 30():194. PubMed ID: 30455823
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Comparison of fluoroquinolone kinetics of kill in susceptible and resistant gram-positive conjunctival pathogens.
    D'Arienzo PA; Wagner RS; Jamison T; Bell B; Dajcs JJ; Stroman DW
    Adv Ther; 2010 Jan; 27(1):39-47. PubMed ID: 20174904
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The comparative in vitro activity of ofloxacin and selected ophthalmic antimicrobial agents against ocular bacterial isolates.
    Osato MS; Jensen HG; Trousdale MD; Bosso JA; Borrmann LR; Frank J; Akers P
    Am J Ophthalmol; 1989 Oct; 108(4):380-6. PubMed ID: 2519514
    [TBL] [Abstract][Full Text] [Related]  

  • 76. In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae.
    Louie A; Brown DL; Liu W; Kulawy RW; Deziel MR; Drusano GL
    Antimicrob Agents Chemother; 2007 Nov; 51(11):3988-4000. PubMed ID: 17846144
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Evaluation of current activities of fluoroquinolones against gram-negative bacilli using centralized in vitro testing and electronic surveillance.
    Sahm DF; Critchley IA; Kelly LJ; Karlowsky JA; Mayfield DC; Thornsberry C; Mauriz YR; Kahn J
    Antimicrob Agents Chemother; 2001 Jan; 45(1):267-74. PubMed ID: 11120976
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [In vitro activities of levofloxacin and other antibiotics against fresh clinical isolates].
    Matsuzaki K; Koyama H; Chiba A; Omika K; Harada S; Sato Y; Hasegawa M; Kobayashi I; Kaneko A; Sasaki J
    Jpn J Antibiot; 1999 Sep; 52(9):571-84. PubMed ID: 10746192
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [The concentrations of fluoroquinolones in prevention of Staphylococcus epidermidis from mutant in ocular surface].
    Sun ST; Chen ZJ; Xu J; Tian XL
    Zhonghua Yan Ke Za Zhi; 2006 Nov; 42(11):989-91. PubMed ID: 17386136
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Antibacterial activity of gatifloxacin against various fresh clinical isolates in 2002].
    Matsuzaki K; Watabe E; Yoshimori K; Shikano M; Sato Y; Hasegawa M; Kobayashi I
    Jpn J Antibiot; 2002 Dec; 55(6):800-7. PubMed ID: 12621734
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.